Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy Biomarkers of DAOIB for Dementia
Sponsor: Chang Gung Memorial Hospital
Summary
This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.
Key Details
Gender
All
Age Range
50 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
123
Start Date
2022-10-03
Completion Date
2026-09
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Locations (2)
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
China Medical University Hospital
Taichung, Taiwan